Plasma homocysteine and oxidative stress in cardiovascular disease

Disease Markers

Volumn 19, Issue 1, 2004, Pages 27-31

  Moselhy, S S ^a   Demerdash, S H ^b  

^a Ain Shams University   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; NITRIC OXIDE; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 1642574272     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/137047     Document Type: Article

References (41)

1. C.M. Ballantyne, Current thinking in lipid lowering, Am J Med 104(6A) (1998), 33S-41S.
2. G. Blundell, B.G. Jones, F.A. Rose and N. Tudball, Homocysteine mediated endothelial cell toxicity and its amelioration, Atherosclerosis 122 (1996), 163-172.
3. C.J. Boushy, S.A. Beresford, G.S. Omenn and A.G. Motulsky, A quantitative assessment of plasma homocysteine as a risk factor for vascular disease probable benefits of increasing folic acid intake, J Am Med Assoc 274 (1995), 1049-1057.
4. D.S. Bredt and S.H. Snyder, Nitric oxide: A physiologic messenger molecule, Ann Rev Biochem 63 (1994), 175-195.
5. D.A. Brouwer, C.B. Leerink, H.N. Steward, T.A. Kroon, G.B. Suverkropp, J.W. Romer, M. Volmer and F.A. Muskiet, Lipids, lipoprotein E genotypes and other risk factors of patients with coronary artery disease in Curacao, West indian Med J 46(2) (1997), 47-52.
6. F.M. Cassone, O. Laurenti, G. Desideri, M.C. Bravi, O. De luca, M.C. Marinucci, G. De Mattia and C. Ferri, L-argnine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in type II diabetic patients, Diabetologia 45(8) (2002), 1120-1127.
7. V. Cavalca, G. Cighetti, F. Bamonti, A. Ioaldi, L. Bortone, C. Novenbrine, M. De franceschi, R. Bclardinelli and M.D. Guazzi, Oxidative stress and homcysteine in coronary artery disease, Clin Chem 47(5) (2001), 887-892.
8. M.T. Christophe, P. Marcel, C.I. Michele, T. Fawzi, A. MicheL and M.L. Jean-Philippe, Plasma homocysteine and severity of thoracic aortic atherosclerosis, Chest 118 (2000), 1685-1689.
9. R. Clarke, L. Daly and K. Robison, Hyperhomocysteinemia: An independent risk factor for vascular disease, NEJM 324 (2001), 1149-1155.
10. A.C. De Olivera, D.C. De Almeida, J.N. Nobregaand S. Tufik, Sleep deprivation reduces total plasma homocysteine levels in rats, Can J Physiol Pharmacol 80(3) (2002), 193-197.
11. M.G. Donner, G.K. Klein, P.B. Mathes, P. Schwandt and W.O. Richter, Plasma total homocysteine levels in patients with early onset coronary heart disease and a low cardiovacular risk profile, Metabolism 47(3) (1998), 273-279.
12. M. Elisaf, The treatment of coronary heart disease: An update Part I; An overview of the risk factors for cardiovascular disease, Curr Med Res Opin 17(1) (2001), 18-26.
13. F. Frantzen, A.L. Faaren, I. Almeim and A.K. Nordhei, An enzyme conversion immunoassay for determining total homocysteine in plasma or serum, Clin. Chem. 44 (1998), 311-316.
14. W.T. Friedwald, R.L. Levy and D.S. Fredickson, Estimation of the concentration of low denisty lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem 18 (1972), 499-502.
15. N. Gorbunov and E. Esposito, Nitric oxide as a mediator of inflammation [Review], Int J Immunopathol Pharmacol 6 (1993), 67-75.
16. L.A. Harker, S.L. Slichter, C.R. Scott and R. Ross, Homocysteinemia: Vascular injury and arterial thrombosis, N Eng J Med 291 (1974), 537-543.
17. R.I. Henary, D.C. Cannon and J.W. Winkelman, Clinical chemistry, principle and techniques, 2nd ed., pp. 1440.
18. W.F. Ignatius, Emerging relations between infectious diseases and coronary artery disease and atherosclerosis, Canadian Medical Association Journal 163(1) (2000), 49-56.
19. M.A. Khan, C.S. Thompson, A.M. Emsley, F.H. Mumtaz, D.P. Mikhailidis, G.D. Angelini, R.J. Morgan and J.Y. Jeremy, The interaction of homocysteine and copper markedly inhibits the relaxation of rabbit corpus cavernosum: new risk factor for angiopathic erectile dysfunction? BJU Int 84 (1999), 720-724.
20. W.K. Kim, S-nitrosoation ameliorates homcysteine induced neurotoxicity and calcium responses in primary culture of rat cortical neurons, Neurosci lett 265 (1999), 99-102.
21. C. Kitiyakara, J. Gonin, Z. Mossy and C.S. Wilcox, Non traditional cardiovascular disease risk factors in end stage renal disease. Oxidative stress and hyperhomocysteinemia, Curr Opin Nephrol Hypertens 5 (2000), 477-487.
22. R.G. Knowles and S. Moncada, Nitric-oxide synthases in mammals [Review], Biochem J 298 (1994), 249-258.
23. J. Loscalzo and G. Welsh, Prog. Cardiovasc. Dis. 38 (1995), 87-104.
24. M.F. Lopes-virella, P. Stone, S. Ellis and J.A. Colwell, Cholesterol determination in high density lipoproteins separated by three different methods, Clin Chem 8 (1977), 882.
25. S.R. Maxwell, Coronary artery disease-free radical damage, antioxidant protection and the role of homocysteine, Basic Res Cardio 195(1) (2000), 165-171.
26. J. McMurray, M. Chopra, I. Abdullah, W.E. Smith and H.J. Dargie Evidence of oxidative stress in chronic heart failure in humans, Eur Heart J 14 (1993), 1493-1498.
27. L.S. Moncada and A. Higgs, The L-argnine-nitric oxide pathway [Review], New Engi J Med 329 (1993), 2002-2012.
28. K. Prasad, Homocysteine, a risk factor for cardiovascular disease, International Journal of angiology 1 (1999), 76-86.
29. S. Penckofer, D. Schwertz and K. Florczak, Oxidative stress and cardiovascular diseases in type 2 diabetes: The role of antioxidant and prooxidants, J cardiovasc. Nurs. 16(2) (2002), 68-85.
30. D. Qujeq, T.S. Omran and L. Hosini, Correlation between total homocysteine, LDL-cholesterol and HDL-cholesterol in the serum of patients with myocardial infarction, Clin Biochem 2 (2001), 97-101.
31. G. Starkebaum and J.M. Harlan, Endothelial cell injury due to copper -catalyzed hydrogen peroxide generation from homocystiene, J Clin Invest 77 (1986), 1370-1376.
32. J.J. Sung and J.E. Sanderson, Hyperhomocysteinemia,Helicobacter Pylori, and coronary heart disease, Heart 76 (1996), 305-307.
33. K. Sydom and R.H. Boger, Homocysteine, endothelial dysfunction and cardiovascular risk: Pathomechanisms and therapeutic options, Z KardioL 90(1) (2001), 1-11.
34. G.R. Upchurch, G.N. Welch, A.J. Fabian, J.E. Freedman, J.L. Johnson, J.F. Keaney and J. Loscaizo, Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase, J Biol Chem 272 (1997), 17012-17017.
35. C. Van Guldener and C.D. Stehouwer, Hyperhomocysteinemia, vascular pathology and endothelial dysfunction, SeminThromb Hemost 26(3) (2000), 81-289.
36. Y. Vodovotz, Modified microassay for serum nitrite and nitrate, Biotechniques 20(3) (1996), 390-394.
37. A.W. Wahlefeld, Triglycerides determination after enzymatic hydrolysis, in: Methods of enzymatic analysis, Bergmeyer, ed., 2nd ed, pp. 1440.
38. J. Wei and M.J. Quast, Effect of nitric oxide synthase inhibitor on a hyperglycemic rat model of reversible focal ischemia;detection of excitatory amino acids release and hydroxyl radical formation, Brain Res 791 (1998), 146-156.
39. G.N. Welch, G.R. Upchurch, R.S. Farivar, A. Pigazzi, K. Vu, P. Brecher, J.F. Keaney and J. Loscaizo, Homocysteine-induced nitric oxide production in vascular smooth muscle cells by NF-Kappa-B-dependent transcriptional activation of NOS 2, Proc Assoc Am Physicions 110(1) (1998), 22-31.
40. F. Zhang, A. Slungaard, G.M. Vercellotti and C. Ladecola, Superoxide dependent cerebrovascular effects of homocysteine, Am J physiol 274 (1998), 1704-1711.
41. T. Zima, S. Stipek, J. Crkovska and J. Platenik, Measurment of lipid peroxidation product-malondialdhyde in biological samples by spectrophotometric and HPLC assay, Klin Bioch Metab 3(24) (1995), 98-102.